Japan Lifeline (7575) Q3 2026 earnings summary

Executive summary

• Nine-month net sales reached a record ¥44,405 million, up 3.7% YoY; operating profit fell 0.8% to ¥9,824 million and net income fell 3.5% to ¥6,821 million.

• Growth in core businesses and new therapeutic areas offset PFA-related pressure; discontinued-product expenses and head-office relocation losses weighed on net income.

• Sales and operating profit were in line with initial guidance; full-year guidance remains unchanged, with a ¥54 per-share year-end dividend forecast.

Financial highlights

• Gross profit rose 2.3% to ¥26,512 million; gross margin was 59.7%, down 80 bps YoY.

• SG&A increased ¥684 million, or 4.3%; operating profit was ¥9,824 million and operating margin was 22.1%, down 100 bps.

• Ordinary profit fell 3.4% to ¥9,608 million, impacted by non-operating expenses related to discontinued products.

• Net income was ¥6,821 million, down 3.5%; basic EPS was ¥97.25, down 2.1%.

• Q3 sales reached a record ¥15,120 million, up 2.0% YoY; net income declined 22.4% amid increased SG&A and extraordinary losses.

Outlook and guidance

• FY2026 guidance is unchanged: sales ¥59,300 million, operating profit ¥12,900 million, net income ¥9,350 million and EPS ¥133.30.

• Nine-month sales and operating profit were 74.9% and 76.2% of full-year guidance; Q4 is expected to track plan, while net income progress is slightly challenging.

• PFA’s negative impact is expected to diminish from Q4 as year-over-year comparisons ease; shorter procedures may support future AF case growth.

• Medium-term targets include 7–8% average annual sales growth, 5–6% operating profit growth, and FY2028 sales of ¥70 billion with an operating margin at the 20% level.